Shixin Qin

This inventor holds 25 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Millennium Pharmaceuticals Limited, Amgen British Columbia Inc., Children's Medical Center Corporation. Active years: 2001-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shixin Qin. Retrieved from https://idiyas.com/inventor/shixin-qin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 4)

% Patents Active = 40.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 134(Granted Patents)

Company Filing History:

17 out of 855

Millennium Pharmaceuticals Limited

patents

2 out of 2

Amgen British Columbia Inc.

patents

2 out of 1,074

Children's Medical Center Corporation

patents

4. 2 out of 2

Critical Therapeutics, Inc.

patents

5. 2 out of 1,429

The Brigham and Women's Hospital, Inc.

patents

6. 2 out of 165

The Feinstein Institutes for Medical Research

patents

7. 1 out of 6

Cornerstone Therapeutics, Inc.

Theodor-Kocher Institute

patents

10. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2021

Loading Chart...

Areas of Expertise:

Anti-GCC Antibody

CXCR3 Antibodies

Monoclonal Antibodies

HMGB1

Eotaxin

Chemokine Receptor

Inflammatory Disease

Leukocyte Inhibition

C-C Chemokine

G Protein-Coupled Receptor

IP-10/Mig Receptor

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10941211 - Anti-GCC antibody molecules and related compositions and methods (2021-03-09),

2. 9163084 - Antibodies which bind human CXCR3 (2015-10-20),

3. 8846047 - Monoclonal antibodies against HMGB1 (2014-09-30),

4. 8785600 - Anti-GCC antibody molecules and related compositions and methods (2014-07-22),

5. 8129130 - High affinity antibodies against HMGB1 and methods of use thereof (2012-03-06),

6. 7994287 - Antibodies which bind human CXCR3 (2011-08-09),

7. 7858326 - Method of diagnosis of inflammatory disease using eotaxin antibodies (2010-12-28),

8. 7632500 - Monoclonal antibodies against HMGB1 (2009-12-15),

9. 7470521 - RAGE protein derivatives (2008-12-30),

10. 7423129 - Antibodies to human eotaxin (2008-09-09),

11. 7407655 - Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody (2008-08-05),

12. 7405275 - Antibodies which bind human CXCR3 (2008-07-29),

13. 7402657 - C-C chemokine receptor 3 proteins (2008-07-22),

14. 7288250 - Monoclonal antibodies against HMGB1 (2007-10-30),

15. 7285620 - Human chemotactic cytokine (2007-10-23),

Title: **Innovative Contributions of Shixin Qin in the Biotech Industry**

Introduction

Shixin Qin, based in Lexington, MA, is an accomplished inventor in the biotech sector, known for his significant contributions to the field of antibody technology. With a remarkable portfolio consisting of 25 patents, Qin has made strides in developing innovative solutions that enhance therapeutic and diagnostic methods.

Latest Patents

Qin's recent patents highlight his dedication to advancing medical science. One of his notable inventions is the development of anti-GCC antibody molecules and related compositions. These antibodies are designed to bind to an extracellular domain of GCC, facilitating internalization into cells. This innovation includes humanized, chimeric, and human antibodies, alongside nucleic acids and vectors encoding these antibodies. The accompanying therapeutic and diagnostic methods open new avenues for cellular targeting in medical treatments.

Additionally, Qin has patented antibodies that bind human CXCR3, once again showcasing his focus on advanced antibody systems. The invention includes compositions comprising the antibodies or antigen-binding fragments and presents therapeutic and diagnostic methods that leverage these antibodies for improved patient outcomes.

Career Highlights

Shixin Qin has had an impactful career, working with Millennium Pharmaceuticals Limited among others in the biotech industry. His expertise in antibody development has been pivotal in the design and creation of targeted therapies, making significant contributions to advancing cancer treatments and other diseases.

Collaborations

Throughout his career, Qin has collaborated with esteemed colleagues, including notable figures such as Walter Newman and Charles R. Mackay. These partnerships have fostered an environment of innovation, leading to the successful development and patenting of groundbreaking technologies in the biotech landscape.

Conclusion

Shixin Qin's work in antibody technologies has paved the way for significant advancements in therapeutic possibilities and diagnostic methods. His innovative spirit continues to inspire professionals in the biotech field, and his numerous patents serve as a testament to his dedication and expertise in transforming healthcare solutions.

Profile summary based on public USPTO records.